Scarsdale J N, Kazanina G, He X, Reynolds K A, Wright H T
Department of Biochemistry, Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, Virginia 23219, USA.
J Biol Chem. 2001 Jun 8;276(23):20516-22. doi: 10.1074/jbc.M010762200. Epub 2001 Mar 8.
Mycolic acids (alpha-alkyl-beta-hydroxy long chain fatty acids) cover the surface of mycobacteria, and inhibition of their biosynthesis is an established mechanism of action for several key front-line anti-tuberculosis drugs. In mycobacteria, long chain acyl-CoA products (C(14)-C(26)) generated by a type I fatty-acid synthase can be used directly for the alpha-branch of mycolic acid or can be extended by a type II fatty-acid synthase to make the meromycolic acid (C(50)-C(56)))-derived component. An unusual Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein (ACP) synthase III (mtFabH) has been identified, purified, and shown to catalyze a Claisen-type condensation between long chain acyl-CoA substrates such as myristoyl-CoA (C(14)) and malonyl-ACP. This enzyme, presumed to play a key role in initiating meromycolic acid biosynthesis, was crystallized, and its structure was determined at 2.1-A resolution. The mtFabH homodimer is closely similar in topology and active-site structure to Escherichia coli FabH (ecFabH), with a CoA/malonyl-ACP-binding channel leading from the enzyme surface to the buried active-site cysteine residue. Unlike ecFabH, mtFabH contains a second hydrophobic channel leading from the active site. In the ecFabH structure, this channel is blocked by a phenylalanine residue, which constrains specificity to acetyl-CoA, whereas in mtFabH, this residue is a threonine, which permits binding of longer acyl chains. This same channel in mtFabH is capped by an alpha-helix formed adjacent to a 4-amino acid sequence insertion, which limits bound acyl chain length to 16 carbons. These observations offer a molecular basis for understanding the unusual substrate specificity of mtFabH and its probable role in regulating the biosynthesis of the two different length acyl chains required for generation of mycolic acids. This mtFabH presents a new target for structure-based design of novel antimycobacterial agents.
分枝菌酸(α-烷基-β-羟基长链脂肪酸)覆盖在分枝杆菌表面,抑制其生物合成是几种关键一线抗结核药物已确立的作用机制。在分枝杆菌中,由I型脂肪酸合酶产生的长链酰基辅酶A产物(C(14)-C(26))可直接用于分枝菌酸的α-分支,或可由II型脂肪酸合酶延长以生成衍生自分枝菌酸(C(50)-C(56))的成分。一种不同寻常的结核分枝杆菌β-酮酰基-酰基载体蛋白(ACP)合酶III(mtFabH)已被鉴定、纯化,并显示可催化长链酰基辅酶A底物(如肉豆蔻酰辅酶A(C(14)))与丙二酰-ACP之间的克莱森型缩合反应。该酶被认为在启动分枝菌酸生物合成中起关键作用,已被结晶,并以2.1埃的分辨率确定了其结构。mtFabH同型二聚体在拓扑结构和活性位点结构上与大肠杆菌FabH(ecFabH)非常相似,有一个从酶表面通向埋藏的活性位点半胱氨酸残基的辅酶A/丙二酰-ACP结合通道。与ecFabH不同,mtFabH含有一个从活性位点引出的第二个疏水通道。在ecFabH结构中,这个通道被一个苯丙氨酸残基阻断,这限制了对乙酰辅酶A的特异性,而在mtFabH中,这个残基是一个苏氨酸,这允许更长酰基链的结合。mtFabH中的这个相同通道由与一个4氨基酸序列插入相邻形成的α-螺旋封闭,这将结合的酰基链长度限制为16个碳。这些观察结果为理解mtFabH不同寻常的底物特异性及其在调节生成分枝菌酸所需的两种不同长度酰基链生物合成中的可能作用提供了分子基础。这种mtFabH为基于结构设计新型抗分枝杆菌药物提供了一个新靶点。